[go: up one dir, main page]

MXPA06002296A - Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos. - Google Patents

Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.

Info

Publication number
MXPA06002296A
MXPA06002296A MXPA06002296A MXPA06002296A MXPA06002296A MX PA06002296 A MXPA06002296 A MX PA06002296A MX PA06002296 A MXPA06002296 A MX PA06002296A MX PA06002296 A MXPA06002296 A MX PA06002296A MX PA06002296 A MXPA06002296 A MX PA06002296A
Authority
MX
Mexico
Prior art keywords
thienopyridine
angiogenic agents
derivatives useful
new anti
phenylacet
Prior art date
Application number
MXPA06002296A
Other languages
English (en)
Inventor
Jihong Lou
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA06002296A publication Critical patent/MXPA06002296A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

La invencion se refiere a compuestos representados por la formula (I): (ver formula (I)) y a profarmacos de los mismos, sales o solvatos farmaceuticamente aceptables de dichos compuestos o de dichos profarmacos, en la que X1-X5 y R1-R5 se ha definido en esta memoria descriptiva. La invencion tambien se refiere a las composiciones farmaceuticas que contienen los compuestos de formula (I) y a metodos de tratamiento de trastornos hiperproliferativos en un mamifero mediante la administracion de compuestos de formula (I).
MXPA06002296A 2003-08-29 2004-08-16 Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos. MXPA06002296A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49907703P 2003-08-29 2003-08-29
PCT/IB2004/002688 WO2005021554A1 (en) 2003-08-29 2004-08-16 Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents

Publications (1)

Publication Number Publication Date
MXPA06002296A true MXPA06002296A (es) 2006-05-22

Family

ID=34272772

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06002296A MXPA06002296A (es) 2003-08-29 2004-08-16 Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.

Country Status (10)

Country Link
US (1) US7208500B2 (es)
EP (1) EP1660504B1 (es)
JP (1) JP2007504122A (es)
AT (1) ATE412655T1 (es)
BR (1) BRPI0413876A (es)
CA (1) CA2536321A1 (es)
DE (1) DE602004017479D1 (es)
ES (1) ES2314444T3 (es)
MX (1) MXPA06002296A (es)
WO (1) WO2005021554A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
JP5096142B2 (ja) 2004-07-30 2012-12-12 メチルジーン インコーポレイテッド Ｖｅｇｆレセプターおよびｈｇｆレセプターシグナル伝達の阻害剤
BRPI0516093A (pt) 2004-10-12 2008-08-19 Astrazeneca Ab derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente
CA2611370C (en) 2005-05-20 2014-11-25 Oscar Mario Saavedra Inhibitors of vegf receptor and hgf receptor signaling
DK1904504T3 (da) 2005-05-20 2014-06-23 Methylgene Inc Inhibitorer af vegf-receptor- og hgf-receptorsignalering
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
JP2009526761A (ja) * 2006-01-30 2009-07-23 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環式チオフェン化合物および使用の方法
UY30183A1 (es) * 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
JP5255559B2 (ja) 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
WO2007113548A1 (en) * 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives
WO2007113565A1 (en) * 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
US20090170131A1 (en) * 2006-05-09 2009-07-02 Juri Gelovani Agents for Imaging Apoptosis
JP2009539878A (ja) * 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
BRPI0908573A2 (pt) 2008-03-05 2012-12-25 Methylgene Inc inibidores da atividade de proteÍna tirosina quinase
BRPI0920261A8 (pt) * 2008-10-14 2016-01-19 Xi Ning Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica
GB0901834D0 (en) 2009-02-04 2009-03-11 Syngenta Ltd Novel herbicides
GB0901835D0 (en) 2009-02-04 2009-03-11 Syngenta Ltd Novel herbicides
MX2011009926A (es) * 2009-03-21 2012-01-27 Ning Xi Derivados de amino esteres, sales de los mismos, y metodos de uso.
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
CA2772625A1 (en) * 2009-09-03 2011-03-10 Allergan, Inc. Compounds as tyrosine kinase modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
WO2013044360A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
WO2013044362A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Selected inhibitors of protein tyrosine kinase activity
CN106046007B (zh) * 2015-04-07 2019-02-05 广东众生睿创生物科技有限公司 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
US11419827B2 (en) 2017-02-24 2022-08-23 Humanetics Corporation Protecting tissue and mitigating injury from radiation-induced ionizing events
US11129894B2 (en) 2017-09-29 2021-09-28 - Humanetics Corporation Sensitizing cells to proton radiation
CN111825605B (zh) * 2019-04-19 2023-03-31 中国科学院上海药物研究所 芳基酮酰胺类化合物及其制备方法和用途

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1995023141A1 (en) 1994-02-23 1995-08-31 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
ES2219670T3 (es) 1994-11-10 2004-12-01 Millennium Pharmaceuticals, Inc. Utilizacion de compuestos de pirazola para el tratamiento de la glomerulonefritis, cancer, ateroesclerosis o restenosis.
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
EP2163546B1 (en) 1995-03-30 2016-06-01 Pfizer Products Inc. Quinazoline derivatives
US5861510A (en) 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DK0831829T3 (da) 1995-06-07 2003-12-15 Pfizer Heterocykliske, ringkondenserede pyrimidinderivater
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
WO1997034876A1 (en) 1996-03-15 1997-09-25 Zeneca Limited Cinnoline derivatives and use as medicine
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
JPH11512750A (ja) 1996-06-27 1999-11-02 ファイザー インク． ２―（２―オキソ―エチリデン）―イミダゾリジン―４―オンの誘導体およびファルネシル蛋白質トランスフェラーゼ阻害物質としてのそれらの使用法
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ES2191187T3 (es) 1996-07-13 2003-09-01 Glaxo Group Ltd Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
EA199900036A1 (ru) 1996-07-18 1999-06-24 Пфайзер Инк Ингибиторы металлопротеаз матрикса на основе фосфинатов, фармацевтическая композиция, способ лечения
PL331895A1 (en) 1996-08-23 1999-08-16 Pfizer Arylosulphonylamino derivatives of hydroxamic acid
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6548524B2 (en) * 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
CA2272705C (en) 1996-11-27 2003-03-18 Pfizer Inc. Fused bicyclic pyrimidine derivatives
DK0950059T3 (da) 1997-01-06 2004-11-01 Pfizer Cycliske sulfonderivater
ATE248812T1 (de) 1997-02-03 2003-09-15 Pfizer Prod Inc Arylsulfonylhydroxamsäurederivate
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
PL334997A1 (en) 1997-02-11 2000-03-27 Pfizer Derivatives or arylosulphonyl-hydroxamic acid
CA2290021A1 (en) 1997-05-12 1998-11-19 The Kennedy Institute Of Rheumatology Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy
WO1998054093A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
US6294532B1 (en) 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
GB9722320D0 (en) 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
CN1280580A (zh) 1997-11-11 2001-01-17 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
AU2825899A (en) * 1998-03-12 1999-09-27 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
AU3850299A (en) 1998-05-20 1999-12-06 Kyowa Hakko Kogyo Co. Ltd. Vegf activity inhibitors
HUP0103617A2 (hu) 1998-05-29 2002-02-28 Sugen, Inc. Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
US6262267B1 (en) * 1998-06-26 2001-07-17 Takeda Chemical Industries, Ltd. Thienopyridine compound
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
WO2000016781A1 (en) 1998-09-18 2000-03-30 Smithkline Beecham Corporation Chk1 kinase inhibitors
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
PL350291A1 (en) 1998-12-23 2002-12-02 Searle & Co Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
DE60038220T2 (de) 1999-08-27 2009-03-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon
PT1218494E (pt) 1999-09-22 2005-08-31 Canbas Co Ltd Composicoes e metodos para inibir a paragem do ciclo celular g2 e para sensibilizar celulas perante agentes que danificam o adn
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
AU2001249393A1 (en) 2000-03-22 2001-10-03 Glaxo Group Limited Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
JP2004501070A (ja) 2000-03-31 2004-01-15 イムクローン　システムズ　インコーポレイティド 血管内皮成長因子受容体アンタゴニストによる非固形哺乳類腫瘍の処理
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
DE60118186T2 (de) 2000-05-12 2006-12-28 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
WO2002030453A1 (en) 2000-10-12 2002-04-18 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting angiogenesis using nadph oxidase inhibitors
PT1339458E (pt) 2000-11-22 2007-11-09 Novartis Ag Combinação compreendendo um agente para diminuir a actividade do vegf e um agente para diminuir a actividade do egf
WO2002064170A1 (en) 2001-02-09 2002-08-22 Children's Medical Center Corporation A method for treating cancer and increasing hematocrit levels
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
WO2003000194A2 (en) * 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
JP2005515967A (ja) 2001-07-13 2005-06-02 イムクローン　システムズ　インコーポレイティド 乳癌を治療するためのｖｅｇｆｒ−１抗体
US20040235867A1 (en) * 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
SI1441714T1 (sl) 2001-10-25 2008-06-30 Novartis Ag Kombinacije, ki obsegajo selektivni inhibitor ciklooksigenaze-2

Also Published As

Publication number Publication date
WO2005021554A1 (en) 2005-03-10
EP1660504B1 (en) 2008-10-29
CA2536321A1 (en) 2005-03-10
US7208500B2 (en) 2007-04-24
EP1660504A1 (en) 2006-05-31
JP2007504122A (ja) 2007-03-01
DE602004017479D1 (de) 2008-12-11
BRPI0413876A (pt) 2006-10-24
US20050090509A1 (en) 2005-04-28
ES2314444T3 (es) 2009-03-16
ATE412655T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
MXPA06002296A (es) Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
GEP20115174B (en) Triazolopyrazine derivatives useful as anti-cancer agents
EA200600892A1 (ru) Новые хинолиновые производные
EA200500814A1 (ru) Производные пирролопиримидина
MXPA02012034A (es) Derivados de tiofeno utiles como agentes anticancerosos.
WO2007138472A3 (en) Triazolopyridazine derivatives
TW200728307A (en) Novel spirochromanone derivatives
MY139357A (en) Novel benzoimidazole derivatives useful as antiproliferative agents
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
WO2003074529A3 (en) iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
BG108650A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
TW200733965A (en) Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
GEP20105134B (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
TW200613243A (en) Novel compounds
TW200806300A (en) New therapeutic combinations for the treatment of depression
MX2007004183A (es) Derivados de benzoimidazol utiles como agentes antiproliferacion.
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
MX2009009466A (es) Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro.
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
TW200639156A (en) New compounds
MX2008012093A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos.
MXPA06000416A (es) Amidas azaheterociclicas novedosas utiles para tratar el dolor.
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
GEP20115216B (en) New phenanthridine derivatives as bradykinin antagonists